Free Trial
TSE:BCT

BriaCell Therapeutics (BCT) Stock Price, News & Analysis

→ A new way to collect income from stocks (From DTI) (Ad)
Free BCT Stock Alerts
C$2.93
-0.08 (-2.66%)
(As of 04/26/2024 ET)
Compare
Today's Range
C$2.91
▼
C$3.01
50-Day Range
C$2.86
▼
C$4.82
52-Week Range
C$2.80
▼
C$10.29
Volume
1,900 shs
Average Volume
8,059 shs
Market Capitalization
C$46.82 million
P/E Ratio
N/A
Dividend Yield
13.70%
Price Target
N/A
Stock AnalysisAnalyst ForecastsChartCompetitorsEarnings

About BriaCell Therapeutics

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

BCT Stock Price History

BCT Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive BCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/18/2024
Today
4/27/2024
Next Earnings (Estimated)
6/12/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
TSE:BCT
CUSIP
N/A
CIK
N/A
Web
www.briacell.com
Phone
604-921-1810
Fax
N/A
Employees
16
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
C($1.07)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
C$-12,610,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-206.01%
Return on Assets
-85.45%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.99
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
C($0.50) per share
Price / Book
-5.86

Miscellaneous

Outstanding Shares
15,980,000
Free Float
N/A
Market Cap
C$46.82 million
Optionable
Not Optionable
Beta
1.74
Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. William V. Williams M.D. (Age 69)
    CEO, President & Director
    Comp: $1.08M
  • Mr. Gadi Levin B.Com. (Age 51)
    C.A., CPA, M.B.A., CFO & Corporate Secretary
    Comp: $419.25k
  • Dr. Miguel A. Lopez-Lago Ph.D. (Age 55)
    Chief Scientific Officer
    Comp: $411.58k
  • Dr. Giuseppe Del Priore M.D. (Age 62)
    M.P.H., MPH, Chief Medical Officer
    Comp: $678.18k
  • Dr. Charles Louis Wiseman FACP (Age 78)
    M.D., Founder, Principal Research Advisor & Member of Scientific Advisory Board
    Comp: $332.05k

Key Competitors

View All Competitors

BCT Stock Analysis - Frequently Asked Questions

Should I buy or sell BriaCell Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BriaCell Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BCT shares.
View BCT analyst ratings or view top-rated stocks.

How have BCT shares performed in 2024?

BriaCell Therapeutics' stock was trading at C$7.80 at the beginning of 2024. Since then, BCT shares have decreased by 62.4% and is now trading at C$2.93.
View the best growth stocks for 2024 here.

When is BriaCell Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024.
View our BCT earnings forecast.

How were BriaCell Therapeutics' earnings last quarter?

BriaCell Therapeutics Corp. (TSE:BCT) posted its quarterly earnings results on Monday, March, 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.68.

How do I buy shares of BriaCell Therapeutics?

Shares of BCT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:BCT) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners
These AI trades triggered this morning (545% return)
Prosper Trading Academy
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
Colonial Metals
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The A.I. story nobody is telling you (Read ASAP)
TradeSmith
Biden out June 13; Kamala won’t replace him?
Paradigm Press
The World's First "$20 Trillion Drug?"
Behind the Markets
They say it’s ‘unstoppable’ – How I made 43,509%
Investing Daily
A.I. is a Tidal Wave - Here’s What to Buy
Chaikin Analytics